According to clinical research, CD19 CAR-T cells from patients who responded well to CAR-T for CLL had more memory T cells, while CD19 CAR-T cells from non-responders had more effector T cells (31). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.